Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05501886




Registration number
NCT05501886
Ethics application status
Date submitted
12/08/2022
Date registered
16/08/2022
Date last updated
1/08/2023

Titles & IDs
Public title
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
Scientific title
Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy
Secondary ID [1] 0 0
2021-005235-24
Secondary ID [2] 0 0
CELC-G-301
Universal Trial Number (UTN)
Trial acronym
VIKTORIA-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Breast Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Breast

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Gedatolisib
Treatment: Drugs - Palbociclib
Treatment: Drugs - Fulvestrant
Treatment: Drugs - Alpelisib

Experimental: Arm A - Patients Lacking PIK3CA Mutations (WT) - Gedatolisib + Palbociclib + Fulvestrant

Experimental: Arm B - Patients Lacking PIK3CA Mutations (WT) - Gedatolisib + Fulvestrant

Active Comparator: Arm C - Patients Lacking PIK3CA Mutations (WT) - Fulvestrant

Experimental: Arm D - Patients with PIK3CA Mutation (MT) - Gedatolisib + Palbociclib + Fulvestrant

Active Comparator: Arm E - Patients with PIK3CA Mutation (MT) - Alpelisib + Fulvestrant

Experimental: Arm F - Patients with PIK3CA Mutation (MT) - Gedatolisib + Fulvestrant


Treatment: Drugs: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off

Treatment: Drugs: Palbociclib
Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off

Treatment: Drugs: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1

Treatment: Drugs: Alpelisib
Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [1] 0 0
Approximately 48 months
Secondary outcome [1] 0 0
Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [1] 0 0
From date of randomization to the date of death due to any cause, up to approximately 48 months
Secondary outcome [2] 0 0
Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [2] 0 0
Up to approximately 48 months
Secondary outcome [3] 0 0
Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [3] 0 0
Up to approximately 48 months
Secondary outcome [4] 0 0
Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [4] 0 0
Up to approximately 48 months
Secondary outcome [5] 0 0
Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [5] 0 0
Up to approximately 48 months
Secondary outcome [6] 0 0
Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [6] 0 0
From baseline to 30 Day Safety Follow-up
Secondary outcome [7] 0 0
Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [7] 0 0
From baseline to 30 Day Safety Follow-up
Secondary outcome [8] 0 0
Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [8] 0 0
From baseline to 30 Day Safety Follow-up
Secondary outcome [9] 0 0
EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer
Timepoint [9] 0 0
From baseline to 30 Day Safety Follow-up
Secondary outcome [10] 0 0
Adverse Events
Timepoint [10] 0 0
Up to approximately 48 months

Eligibility
Key inclusion criteria
1. Histologically or cytologically confirmed diagnosis of metastatic or locally advanced
breast cancer Adult females, pre- and/or post-menopausal, and adult males.
Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment
with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH
agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the
duration of the study.

2. Negative pregnancy test for women of childbearing potential. Female subjects of
childbearing potential must use an effective and/or acceptable contraceptive method
from screening until 1 year after the last dose of study treatment

3. Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor
positive, as per American Society of Clinical Oncology/College of American
Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing
an assay consistent with local standards

4. Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance

5. Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status

6. Subject must have documentation of radiological disease progression on or after the
last prior treatment and also have radiologically evaluable disease (measurable and/or
non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone
only disease must have lytic or mixed lytic/blastic lesions that can be accurately
assessed; bone only blastic lesions with no soft tissue component is not allowed.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

8. Life expectancy of at least 3 months

9. Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal
aromatase inhibitor (AI)

10. Adequate bone marrow, hepatic, renal and coagulation function
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History of malignancies other than adequately treated non-melanoma skin cancer,
curatively treated in situ cancer of the cervix, or other solid tumors curatively
treated with no evidence of disease for =3 years

2. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B
(Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor

3. Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is
not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)

4. More than 2 lines of prior endocrine therapy treatment

5. Bone only disease that is only blastic with no soft tissue component

6. Subjects with type 1 diabetes or uncontrolled type 2 diabetes

7. Known and untreated, or active, brain or leptomeningeal metastases

a. Subjects with previously treated central nervous system (CNS) metastases may be
enrolled in the study if they meet the following criteria: do not require supportive
therapy with steroids; do not have seizures and do not exhibit uncontrolled
neurological symptoms; stable disease confirmed by radiographic assessment within at
least 4 weeks prior to enrollment

8. Patients with advanced, symptomatic, visceral spread that are at risk of
life-threatening complication in the short-term

9. History of clinically significant cardiovascular abnormalities such as: Congestive
heart failure (New York Heart Association (NYHA) classification = II within 6 months
of study entry

1. Myocardial infarction within 12 months of study entry

2. History of any uncontrolled (or untreated) clinically significant cardiac
arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block,
high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV
block), supraventricular, nodal arrhythmias, or conduction abnormality in the
previous 12 months

3. Uncontrolled hypertension defined by systolic blood pressure (SBP) =160 mmHg
and/or diastolic blood pressure (DBP) =100 mmHg, with or without antihypertensive
medication (initiation or adjustment of antihypertensive medication[s] is allowed
prior to screening)

4. Long QT syndrome, family history of idiopathic sudden death or congenital long QT
syndrome, or any of the following:

- i. Risk factors for Torsades de Pointes (TdP) including uncorrected
hypokalemia or hypomagnesemia, or history of clinically
significant/symptomatic bradycardia

- ii. On screening, inability to determine the corrected QT interval using
Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not
interpretable) or QTcF >480 msec (determined by mean of triplicate ECGs at
screening)

10. Known hypersensitivity to the study drugs or their components

11. Pregnant or breast-feeding women

12. Concurrent participation in another interventional clinical trial

1. Subjects must agree not to participate in another clinical trial (other than
observational) at any time during participation in VIKTORIA-1.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/09/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
30/09/2026
Actual
Sample size
Target
701
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Adelaide Oncology & Haematology - Adelaide
Recruitment hospital [2] 0 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [3] 0 0
Peninsula & South Eastern Hematology and Oncology Group (PSEHOG) - Frankston
Recruitment hospital [4] 0 0
Hollywood Private Hospital, Breast Cancer Research Centre - Nedlands
Recruitment hospital [5] 0 0
Mater Hospital Brisbane, Mater Cancer Care Centre - South Brisbane
Recruitment hospital [6] 0 0
Icon Cancer Centre- Southport - Southport
Recruitment hospital [7] 0 0
Sydney Adventist Hospital - Wahroonga
Recruitment hospital [8] 0 0
The Queen Elizabeth Hospital - Woodville
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Fitzroy
Recruitment postcode(s) [3] 0 0
- Frankston
Recruitment postcode(s) [4] 0 0
- Nedlands
Recruitment postcode(s) [5] 0 0
- South Brisbane
Recruitment postcode(s) [6] 0 0
- Southport
Recruitment postcode(s) [7] 0 0
- Wahroonga
Recruitment postcode(s) [8] 0 0
- Woodville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
Arkansas
Country [4] 0 0
United States of America
State/province [4] 0 0
California
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Maryland
Country [12] 0 0
United States of America
State/province [12] 0 0
Massachusetts
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Nebraska
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Oklahoma
Country [19] 0 0
United States of America
State/province [19] 0 0
Oregon
Country [20] 0 0
United States of America
State/province [20] 0 0
Pennsylvania
Country [21] 0 0
United States of America
State/province [21] 0 0
South Dakota
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Virginia
Country [24] 0 0
United States of America
State/province [24] 0 0
Washington
Country [25] 0 0
Argentina
State/province [25] 0 0
Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Córdoba
Country [27] 0 0
Argentina
State/province [27] 0 0
Paraná
Country [28] 0 0
Argentina
State/province [28] 0 0
Salta
Country [29] 0 0
Argentina
State/province [29] 0 0
San Juan
Country [30] 0 0
Argentina
State/province [30] 0 0
Santa Fe
Country [31] 0 0
Argentina
State/province [31] 0 0
Tucumán
Country [32] 0 0
Austria
State/province [32] 0 0
Graz
Country [33] 0 0
Austria
State/province [33] 0 0
Innsbruck
Country [34] 0 0
Austria
State/province [34] 0 0
Linz
Country [35] 0 0
Austria
State/province [35] 0 0
Salzburg
Country [36] 0 0
Austria
State/province [36] 0 0
St. Poelten
Country [37] 0 0
Austria
State/province [37] 0 0
Vienna
Country [38] 0 0
Belgium
State/province [38] 0 0
Brussels
Country [39] 0 0
Belgium
State/province [39] 0 0
Charleroi
Country [40] 0 0
Belgium
State/province [40] 0 0
Edegem
Country [41] 0 0
Belgium
State/province [41] 0 0
Kortrijk
Country [42] 0 0
Belgium
State/province [42] 0 0
Leuven
Country [43] 0 0
Belgium
State/province [43] 0 0
Liège
Country [44] 0 0
Belgium
State/province [44] 0 0
Sint-Niklaas
Country [45] 0 0
Belgium
State/province [45] 0 0
Verviers
Country [46] 0 0
Belgium
State/province [46] 0 0
Yvoir
Country [47] 0 0
Brazil
State/province [47] 0 0
Pará
Country [48] 0 0
Brazil
State/province [48] 0 0
Fortaleza
Country [49] 0 0
Brazil
State/province [49] 0 0
Ijuí
Country [50] 0 0
Brazil
State/province [50] 0 0
Minas Gerais
Country [51] 0 0
Brazil
State/province [51] 0 0
Salvador de Bahia
Country [52] 0 0
Brazil
State/province [52] 0 0
São Paulo
Country [53] 0 0
Bulgaria
State/province [53] 0 0
Panagyurishte
Country [54] 0 0
Bulgaria
State/province [54] 0 0
Sofia
Country [55] 0 0
Bulgaria
State/province [55] 0 0
Varna
Country [56] 0 0
Canada
State/province [56] 0 0
British Columbia
Country [57] 0 0
Canada
State/province [57] 0 0
Quebec
Country [58] 0 0
Czechia
State/province [58] 0 0
Olomouc
Country [59] 0 0
Czechia
State/province [59] 0 0
Prague
Country [60] 0 0
France
State/province [60] 0 0
Bordeaux
Country [61] 0 0
France
State/province [61] 0 0
Caen
Country [62] 0 0
France
State/province [62] 0 0
La Roche-sur-Yon
Country [63] 0 0
France
State/province [63] 0 0
Marseille
Country [64] 0 0
France
State/province [64] 0 0
Poitiers
Country [65] 0 0
France
State/province [65] 0 0
Strasbourg
Country [66] 0 0
France
State/province [66] 0 0
Villejuif
Country [67] 0 0
Germany
State/province [67] 0 0
Bayreuth
Country [68] 0 0
Germany
State/province [68] 0 0
Berlin
Country [69] 0 0
Germany
State/province [69] 0 0
Luebeck
Country [70] 0 0
Germany
State/province [70] 0 0
Mainz
Country [71] 0 0
Germany
State/province [71] 0 0
Mecklenburg
Country [72] 0 0
Germany
State/province [72] 0 0
Münster
Country [73] 0 0
Germany
State/province [73] 0 0
Saarbrücken
Country [74] 0 0
Germany
State/province [74] 0 0
Wuppertal
Country [75] 0 0
Greece
State/province [75] 0 0
Athens
Country [76] 0 0
Greece
State/province [76] 0 0
Ioánnina
Country [77] 0 0
Greece
State/province [77] 0 0
Larissa
Country [78] 0 0
Greece
State/province [78] 0 0
Thessaloníki
Country [79] 0 0
Hungary
State/province [79] 0 0
Debrecen
Country [80] 0 0
Hungary
State/province [80] 0 0
Kecskemét
Country [81] 0 0
Hungary
State/province [81] 0 0
Nyíregyháza
Country [82] 0 0
India
State/province [82] 0 0
Bangalore
Country [83] 0 0
India
State/province [83] 0 0
Chandigarh
Country [84] 0 0
India
State/province [84] 0 0
Kolkata
Country [85] 0 0
India
State/province [85] 0 0
Navi Mumbai
Country [86] 0 0
India
State/province [86] 0 0
Vellore
Country [87] 0 0
Italy
State/province [87] 0 0
Milan
Country [88] 0 0
Italy
State/province [88] 0 0
Modena
Country [89] 0 0
Italy
State/province [89] 0 0
Monza
Country [90] 0 0
Italy
State/province [90] 0 0
Parma
Country [91] 0 0
Italy
State/province [91] 0 0
Prato
Country [92] 0 0
Italy
State/province [92] 0 0
Rome
Country [93] 0 0
Italy
State/province [93] 0 0
Udine
Country [94] 0 0
Korea, Republic of
State/province [94] 0 0
Seoul
Country [95] 0 0
Korea, Republic of
State/province [95] 0 0
Soeul
Country [96] 0 0
Korea, Republic of
State/province [96] 0 0
Ulsan
Country [97] 0 0
Mexico
State/province [97] 0 0
Mexico City
Country [98] 0 0
Mexico
State/province [98] 0 0
Monterrey
Country [99] 0 0
Mexico
State/province [99] 0 0
Morelia
Country [100] 0 0
Mexico
State/province [100] 0 0
Nuevo León
Country [101] 0 0
Mexico
State/province [101] 0 0
Querétaro
Country [102] 0 0
Mexico
State/province [102] 0 0
Saltillo
Country [103] 0 0
Poland
State/province [103] 0 0
Bydgoszcz
Country [104] 0 0
Poland
State/province [104] 0 0
Konin
Country [105] 0 0
Poland
State/province [105] 0 0
Kraków
Country [106] 0 0
Poland
State/province [106] 0 0
Opole
Country [107] 0 0
Poland
State/province [107] 0 0
Siedlce
Country [108] 0 0
Poland
State/province [108] 0 0
Szczecin
Country [109] 0 0
Poland
State/province [109] 0 0
Warsaw
Country [110] 0 0
Poland
State/province [110] 0 0
Wroclaw
Country [111] 0 0
Poland
State/province [111] 0 0
Lódz
Country [112] 0 0
Romania
State/province [112] 0 0
Baia Mare
Country [113] 0 0
Romania
State/province [113] 0 0
Bucharest
Country [114] 0 0
Romania
State/province [114] 0 0
Cluj-Napoca
Country [115] 0 0
Romania
State/province [115] 0 0
Craiova
Country [116] 0 0
Romania
State/province [116] 0 0
Târgu-Mures
Country [117] 0 0
Singapore
State/province [117] 0 0
Singapore
Country [118] 0 0
Spain
State/province [118] 0 0
Badajoz
Country [119] 0 0
Spain
State/province [119] 0 0
Barcelona
Country [120] 0 0
Spain
State/province [120] 0 0
Cáceres
Country [121] 0 0
Spain
State/province [121] 0 0
Madrid
Country [122] 0 0
Spain
State/province [122] 0 0
Murcia
Country [123] 0 0
Spain
State/province [123] 0 0
Santiago De Compostela
Country [124] 0 0
Taiwan
State/province [124] 0 0
Kaohsiung
Country [125] 0 0
Taiwan
State/province [125] 0 0
New Taipei City
Country [126] 0 0
Taiwan
State/province [126] 0 0
Taichung
Country [127] 0 0
Taiwan
State/province [127] 0 0
Tainan
Country [128] 0 0
Taiwan
State/province [128] 0 0
Taipei
Country [129] 0 0
United Kingdom
State/province [129] 0 0
Bath
Country [130] 0 0
United Kingdom
State/province [130] 0 0
Cardiff
Country [131] 0 0
United Kingdom
State/province [131] 0 0
London
Country [132] 0 0
United Kingdom
State/province [132] 0 0
Manchester
Country [133] 0 0
United Kingdom
State/province [133] 0 0
Nottingham

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Celcuity Inc
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety
of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients
with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after
CDK4/6 and aromatase inhibitor therapy.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05501886
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Nadene Zack
Address 0 0
Celcuity Inc
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Nadene Zack, MS
Address 0 0
Country 0 0
Phone 0 0
844-310-3900
Fax 0 0
Email 0 0
VIKTORIA-1_TRIAL@CELCUITY.COM
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05501886